The effect of diluted 1% baby shampoo on biofilm reduction in chronic rhinosinusitis with nasal polyposis
Journal
PeerJ
Year
2025
Background
Biofilm has been identified as the contributing factor for refractory chronic rhinosinusitis with nasal polyposis (CRSwNP). Nasal douching using baby shampoo was thought to be effective in patients with CRSwNP. We aimed to study the in-vitro reduction of biofilm using diluted 1% baby shampoo.
Materials & Methods
Sixty nasal polyps taken from patients who met the inclusion and exclusion criteria were sent for histopathological examination using haematoxylin and eosin staining. Another portion of the same samples was sent for tissue culture and tissue culture plate assay to identify S. aureus and P. aeruginosa and determine their biofilm forming capacity. The efficacy of diluted 1% baby shampoo versus normal saline was tested on the biofilm in vitro where the optical density readings were compared pre- and post-treatment.
Conclusion
In conclusion, diluted 1% baby shampoo is an effective treatment in the reduction of biofilm for CRSwNP.
Resources and Links
Phone Number: +603 2781 4519 / +603 2781 4520
https://peerj.com/articles/19134/
Share the Page
|
|
Information
Consultant Name
Dato' Dr Balwant Singh Gendeh
For general questions about clinical trials
Phone Number: +603 2781 4519 / +603 2781 4520
Clinical trials are part of research studies involving patient volunteers that are conducted to find safe and effective treatments for a variety of health conditions. They are critical to the advancement of medicine and improving patient health. Participating in clinical trials offers patients the opportunity to try new and effective treatments that could potentially improve their condition while taking part in vital research that can benefit many future patients.
In Pantai Hospital Kuala Lumpur, clinical trials are carried out under our Clinical Research team.
If you would like to participate in any of our clinical trials or would like to know, please provide your information below and we will be in touch with you:


